lynx   »   [go: up one dir, main page]


Life Sciences

Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.

EY Biotech Beyond Borders Report 2025

Find out how biotech companies and life sciences leaders are managing uncertainty and preparing to bounce back across the biotechnology landscape. 

Our latest thinking

How next-generation CRM will reshape the life sciences commercial model

CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights—transform your customer engagement now. Read more.

EY Biotech Beyond Borders Report 2025

Biotech companies and life sciences leaders are managing uncertainty and preparing to bounce back across the biotechnology landscape. Find out how.

How biopharma can get the right mix of people and tech for launch success

Facing a challenging commercial environment, biopharma companies need to embrace an end-to-end, AI-driven strategy to succeed. Read more.

The Unstoppables: Success stories of the world’s most inspiring entrepreneurs

The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.

Pulse of the MedTech Industry report 2024

2024 EY MedTech report on dealmaking, financing, and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.

Jim Welch + 2

Why licensing deals are a powerful source of growth in life sciences

Innovation is key in Life Sciences. In response to challenges, pharmaceutical companies increasingly turn to external innovation, leveraging licensing deals. Learn more.

How AI is supporting pharmaceutical manufacturing and supply chain

In this episode, listeners will hear how AI is playing an increasingly important role in pharma manufacturing. Learn more.

24m 13s

What pharma supply chain transformation means for tax

Businesses looking to create visibility and resilience in their supply chains must loop in tax and transfer pricing teams early in the process. Learn more.

How life sciences can make the right deals in a time of change

Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.

How will you respond to clinicians sounding the alarm on unsustainable care delivery models?

The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.

Why digital supply chain visibility should be a pharma priority

With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.

How digital is changing the tax strategy for MedTech

As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.

How Takeda accelerated the financial close process by nearly two weeks

In this case study, learn how leading pharmaceutical company Takeda is creating value for patients through finance innovation and process excellence.

How early diagnosis can transform health care

Mirxes’ Dr. Zhou Lihan shares his purpose and passion for a more proactive approach to medicine. Learn more.

How innovation can unlock the power of data to deliver value-based care

Organizations have the tools to deliver a better personalized health experience, but the ecosystem needs to collaborate to build this future. Learn more.

How life sciences businesses transform the tax and finance function

Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.

Why life sciences tax departments need to act now on sustainability

Life sciences organizations should consider tax liabilities and compliance obligations resulting from myriad new sustainability taxes. Learn more.

How do you build future supply chains to best serve patient needs?

In the wake of global disruptions, EY research aims to map out the future for supply chain transformation in the pharmaceutical industry. Read more.

How CDMOs are leading innovation for pharmaceutical partners

Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.

What going digital means for Takeda

Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.

How to navigate global TP controversy in life sciences — Asia-Pacific and Europe focus

In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in Asia-Pacific and Europe. Learn more.

How to navigate global TP controversy in life sciences — US focus

In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in the US. Learn more.

How to navigate global transfer pricing controversy in life sciences

Life sciences companies face growing tax authority scrutiny of their transfer pricing practices and must prepare for escalating controversy.

How you can create value in an intelligent health ecosystem

The intelligent health ecosystem will provide smarter insights and personalized health care experiences to patients, anytime and anywhere.

How to navigate EU regulations for drug-device combination products

The new EU Medical Device Regulation (MDR) creates significant regulatory challenges for drug-device combination (DDC) product manufacturers.

How one entrepreneur seeks to make affordable health care a reality

Celltrion’s JungJin SEO shares his purpose and passion for more accessible health care. Learn more.

How data can help redesign the health experience

In this episode of the EY Health Sciences and Wellness Experience Podcast, Pamela Spence discusses the importance of data and how it can help redesign the health experience. Learn more.

16m 52s

How ecosystem participation drives more value for life sciences deals

Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.

How to account for outcome-based payment arrangements in life sciences

The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.

 How the future of health care is becoming a reality

Human-centric care will soon become a reality, driven by data and technology.

Five trends redefining the health sciences and wellness operating model 

As demand from consumers accelerates the adoption of new technologies, we explore how companies can provide a more convenient health experience.


    Close up of hand touching smartwatch with health app
    Optimizing health outcomes for all

    Discover key insights that highlight strategic priorities and investments to enhance care across sectors, along with the evolution of organizational capabilities, based on a survey of 500 industry leaders.

    Read the report (via ey.com US)


    How AI can support decision-making in drug development portfolios

    For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.

    Learn more (via ey.com US)

    A female scientist in a lab



    Case studies

    How Sigma, an Australian pharmaceutical company, transformed its supply chain

    Discover how EY teams helped Sigma simplify and standardize to boost availability and cut inventory by 20%.

    How Medtronic’s optimized supply chain gets products to patients in need

    A global technology Life Sciences leader improved their supply chain planning to better serve patients. Learn more in this case study.

    How IntraBio's finance transformation fueled its global expansion

    For its global expansion, IntraBio needed to solve operational and financial back-office challenges. Learn how EY finance transformation services helped.

    How St James’s Hospital's transformed cancer care

    Learn how our client modernized its infrastructure enhancing its data management and speeding up cancer diagnostics.

    How tech and trust transformed a tax operating model

    Global pharmaceutical player Boehringer Ingelheim is reimaging its tax operating model to boost quality and efficiency. Learn more in this case study.

    How Bayer is unearthing agronomy's future with generative AI

    Read this case study to learn how Bayer Crop Science is using large language models to plant the seeds of the future.

    How a global biopharma became a leader in ethical AI

    Read this case study about how a science-led biopharma positioned itself as a leader in ethical AI.

      Contact us
      Like what you’ve seen? Get in touch to learn more.
      Лучший частный хостинг